William Blair Comments on Hologic, Inc.’s FY2024 Earnings (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) – William Blair increased their FY2024 EPS estimates for Hologic in a research note issued on Friday, May 3rd. William Blair analyst A. Brackmann now forecasts that the medical equipment provider will post earnings per share of $4.07 for the year, up from their prior estimate of $3.97. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Hologic’s current full-year earnings is $4.08 per share. William Blair also issued estimates for Hologic’s Q4 2024 earnings at $1.03 EPS, Q1 2025 earnings at $1.06 EPS, Q2 2025 earnings at $1.08 EPS, Q3 2025 earnings at $1.13 EPS, Q4 2025 earnings at $1.18 EPS and FY2025 earnings at $4.45 EPS.

A number of other research firms have also weighed in on HOLX. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. UBS Group raised their price target on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, February 2nd. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Raymond James boosted their price objective on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Finally, Evercore ISI raised their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus target price of $84.56.

Hologic Stock Performance

NASDAQ HOLX opened at $76.10 on Monday. The business’s 50 day moving average price is $76.16 and its 200-day moving average price is $73.20. Hologic has a fifty-two week low of $64.02 and a fifty-two week high of $86.74. The company has a market cap of $17.86 billion, a P/E ratio of 38.83, a P/E/G ratio of 2.55 and a beta of 1.01. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the firm posted $1.06 EPS. The business’s quarterly revenue was down .8% on a year-over-year basis.

Insiders Place Their Bets

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of HOLX. Massmutual Trust Co. FSB ADV increased its holdings in shares of Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares in the last quarter. Graypoint LLC grew its position in Hologic by 3.9% during the first quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after buying an additional 147 shares during the period. Deseret Mutual Benefit Administrators increased its holdings in Hologic by 42.2% in the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 155 shares in the last quarter. Arizona State Retirement System raised its position in shares of Hologic by 0.3% in the fourth quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock worth $4,810,000 after acquiring an additional 172 shares during the period. Finally, Lincoln National Corp grew its position in shares of Hologic by 4.0% during the 4th quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock valued at $334,000 after acquiring an additional 178 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.